Infectious Diseases 1203 - Infectious Disease Alert - Mar 01, 2008

Target Audience:

This activity is intended for the infectious disease specialist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Stan Deresinski, MD, FACP
Clinical Professor of Medicine
Stanford
Associate Chief of Infectious Diseases
Santa Clara Valley Medical Center

Board Member and Peer Reviewer
Connie Price, MD
Assistant Professor
University of Colorado School of Medicine

Board Member and Updates Author
Carol A. Kemper, MD, FACP
Clinical Associate Professor of Medicine
Stanford University
Division of Infectious Diseases
Santa Clara Valley Medical Center
Section Editor, Updates
Section Editors, HIV

Associate Editors
Dean L. Winslow, MD, FACP, FIDSA
Chief, Division of AIDS Medicine
Santa Clara Valley Medical Center
Clinical Professor
Stanford University School of Medicine
Section Editor, HIV

Jessica Song, PharmD
Pharmacy Residency Coordinator
Assistant Professor, Pharmacy Practice
University of the Pacific
Stockton, CA
Pharmacy Clerkship and Coordinator
Santa Clara Valley Medical Center
Section Editor, Managed Care

Robert Muder, MD
Hospital Epidemiologist
Pittsburgh VA Medical Center
Section Editor, Hospital Epidemiology

Authors
Lian Chang, PharmD Candidate
University of the Pacific

John O'Brien, PharmD Candidate
Clinical Pharmacist Specialist
Santa Clara Valley Health and Hospital System

Subjects:

  • Relationship between Tenofovir-Associated Renal Dysfunction and HAART Regimen
  • A New Class of Antiretrovirals: Isentress┬« (Raltegravir)
  • S. maltophilia: A Multi-Resistant Nosocomial Pathogen
  • Updates

Objectives:

  • discuss the diagnosis and treatment of infectious diseases
  • present current data regarding the use of new antibiotics for commonly diagnosed diseases and new uses for traditional drugs
  • present the latest information regarding the pros, cons, and cost-effectiveness of new and traditional diagnostic tests
  • discuss new information regarding how infectious diseases (eg, AIDS) are transmitted and how such information can lead to the development of new therapy

Financial Disclosure:

Infectious Disease Alert's Physician Editor, Stan Deresinski, MD, FACP, serves on the speaker's bureau of Merck, Pharmacia, GlaxoSmithKline, Pfizer, Bayer, and Wyeth, and does research for Merck.

Peer Reviewer Connie Price, MD, reports no consultant, stockholder, speaker's bureau, research, or other financial relationship with any company related to this field of study.

Updates author Carol A. Kemper, MD, FACP reports no financial relationships relevant to this field of study.

Authors Brian G. Blackburn, MD, Jennifer L. Kruse , and Philip R. Fischer reports no financial relationships relevant to this field of study.

Associate Editor Dean L. Winslow, MD, FACP, FIDSA, serves as a consultant for Siemens Diagnostics, and is on the speaker's bureau for Boehringer-Ingelheim and GSK.

Associate Editor Hal B. Jenson, MD, is on the speaker's bureau for Merck.

Associate Editor Joseph F. John, MD, FACP, FIDSA, FSHEA, is a consultant for Cubist, Genzyme, and bioMerieux, and is on the speaker's bureau for Cubist, GSK, Merck, Bayer, and Wyeth.

Copyright 2008 AHC Media. All rights reserved.